Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

FDA Grants Fast Track Designation to CER-1236 in Acute Myeloid Leukemia

September 5th 2025

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

Lunresertib and Other PKMYT1 Inhibitors Show Promise in Gynecologic Malignancies

September 5th 2025

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia

September 4th 2025

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

Zanubrutinib Prolongs PFS, Shows Trend Toward Improved OS in MAIC Analysis in CLL

September 4th 2025

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

How Fellows Can Leverage Mentorship to Maximize Research Opportunities

September 2nd 2025

The director of the Hematology and Oncology Fellowship Program at Weill Cornell Medicine details how fellows can identify and maximize research opportunities.

Molecular Research With Benign, Self-Limiting Bone Lesion May Unlock New Treatment Avenues for RAS/MAPK-Activated Tumors

August 29th 2025

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Perioperative Tislelizumab Wins EU Approval for Resectable NSCLC at High Risk of Recurrence

August 27th 2025

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy Improves OS in High-Risk HR+/HER2– Breast Cancer

August 27th 2025

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

UGN-102 Redefines Treatment Standards for Low-Grade, Intermediate-Risk NMIBC

August 27th 2025

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

EMA Grants Orphan Drug Designation to Pegtarazimod for GVHD

August 23rd 2025

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies

August 22nd 2025

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Fruquintinib Efficacy Data Support Its Use in the Third-Line Advanced CRC Setting

August 20th 2025

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

FDA Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

August 20th 2025

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Health Canada Approves Nivolumab Plus Ipilimumab for Unresectable MSI-H/dMMR CRC and Unresectable HCC

August 20th 2025

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20th 2025

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies

August 18th 2025

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Phase 2/3 Trial Further Evaluates Ficerafusp Alfa With Pembrolizumab in HPV– Head and Neck Cancer

August 18th 2025

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

Working Smarter to Unpack the Challenges of a New Cancer Diagnosis

August 16th 2025

Ashish Saxena, MD, PhD, discusses how fellows can make the discussion of an initial cancer diagnosis as productive as possible for patients.

Understanding Hematology/Oncology Clinical Trials Is Crucial to Patient Communication

August 15th 2025

Matthew Hadfield, DO, discusses how hematology/oncology fellows should approach the interpretation of clinical trial data.